08:00 , Jan 4, 2000 |  BioCentury  |  Finance

1999 M&A activity

1999 M&A activity Company Acquired or merged company Value (M) Johnson & Johnson Centocor $4,900.0 Roche Genentech $4,200.0 Warner-Lambert Agouron $2,100.0 Shire Roberts $1,000.0 Celltech Medeva $912.0 Millennium LeukoSite $910.0 Pharmacia & Upjohn Sugen $728.5...
07:00 , Jun 7, 1999 |  BC Week In Review  |  Company News

Aptein, Cambridge Antibody deal

CAT issued 1.1 million common shares valued at $5 million to Aptein shareholders to complete the purchase of Aptein for a total of $11 million (see BioCentury, June 29, 1998). The issue was triggered by...
07:00 , Jun 7, 1999 |  BioCentury  |  Finance

Greater fools at play

When the relentlessly efficient market casts a vote, it's usually right. And if it's wrong, it's usually not wrong by much. However, investors' belief that Roche would not exercise its option to acquire the rest...
07:00 , Jul 27, 1998 |  BC Week In Review  |  Company News

Aptein, Cambridge Antibody deal

Aptein received a European patent covering its polysome display technology, an event that triggered the closing of CAT's purchase of Aptein (see BioCentury, June 29). Aptein Inc., Seattle, Wash.   Cambridge Antibody Technology Group plc...
07:00 , Jun 29, 1998 |  BC Week In Review  |  Company News

Aptein, Cambridge Antibody deal

CAT will purchase Aptein, a developer of ribosome (polysome) display technology, for $11 million through the issue of up to 2.4 million CAT shares. Upon the close of the transaction, CAT will issue 1.3 million...
07:00 , Sep 8, 1997 |  BC Week In Review  |  Clinical News

Aptein regulatory update

Aptein received two U.S. patents, Nos. 5,643,768 and 5,658,754, covering in vitro translation "polysome display" methods for screening large libraries of random peptides. The screening uses "polysomes" comprised of a random peptide and the peptide's...